Cargando…

Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs

BACKGROUND: The resistance against antimalarial drugs represents a global challenge in the fight and control of malaria. The Brazilian biodiversity can be an important tool for research and development of new medicinal products. In this context, toxinology is a multidisciplinary approach on the deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Banfi, Felipe Finger, Krombauer, Gabriela Camila, da Fonseca, Amanda Luisa, Nunes, Renata Rachide, Andrade, Silmara Nunes, de Rezende, Millena Alves, Chaves, Mariana Helena, Monção, Evaldo dos Santos, Taranto, Alex Guterres, Rodrigues, Domingos de Jesus, Vieira, Gerardo Magela, de Castro, Whocely Victor, Varotti, Fernando de Pilla, Sanchez, Bruno Antonio Marinho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Estudos de Venenos e Animais Peçonhentos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812938/
https://www.ncbi.nlm.nih.gov/pubmed/33519927
http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0073
_version_ 1783637755309326336
author Banfi, Felipe Finger
Krombauer, Gabriela Camila
da Fonseca, Amanda Luisa
Nunes, Renata Rachide
Andrade, Silmara Nunes
de Rezende, Millena Alves
Chaves, Mariana Helena
Monção, Evaldo dos Santos
Taranto, Alex Guterres
Rodrigues, Domingos de Jesus
Vieira, Gerardo Magela
de Castro, Whocely Victor
Varotti, Fernando de Pilla
Sanchez, Bruno Antonio Marinho
author_facet Banfi, Felipe Finger
Krombauer, Gabriela Camila
da Fonseca, Amanda Luisa
Nunes, Renata Rachide
Andrade, Silmara Nunes
de Rezende, Millena Alves
Chaves, Mariana Helena
Monção, Evaldo dos Santos
Taranto, Alex Guterres
Rodrigues, Domingos de Jesus
Vieira, Gerardo Magela
de Castro, Whocely Victor
Varotti, Fernando de Pilla
Sanchez, Bruno Antonio Marinho
author_sort Banfi, Felipe Finger
collection PubMed
description BACKGROUND: The resistance against antimalarial drugs represents a global challenge in the fight and control of malaria. The Brazilian biodiversity can be an important tool for research and development of new medicinal products. In this context, toxinology is a multidisciplinary approach on the development of new drugs, including the isolation, purification, and evaluation of the pharmacological activities of natural toxins. The present study aimed to evaluate the cytotoxicity, as well as the antimalarial activity in silico and in vitro of four compounds isolated from Rhinella marina venom as potential oral drug prototypes. METHODS: Four compounds were challenged against 35 target proteins from P. falciparum and screened to evaluate their physicochemical properties using docking assay in Brazilian Malaria Molecular Targets (BraMMT) software and in silico assay in OCTOPUS® software. The in vitro antimalarial activity of the compounds against the 3D7 Plasmodium falciparum clones were assessed using the SYBR Green I based assay (IC(50)). For the cytotoxic tests, the LD(50) was determined in human pulmonary fibroblast cell line using the [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. RESULTS: All compounds presented a ligand-receptor interaction with ten Plasmodium falciparum-related protein targets, as well as antimalarial activity against chloroquine resistant strain (IC(50) = 3.44 μM to 19.11 μM). Three of them (dehydrobufotenine, marinobufagin, and bufalin) showed adequate conditions for oral drug prototypes, with satisfactory prediction of absorption, permeability, and absence of toxicity. In the cell viability assay, only dehydrobufotenin was selective for the parasite. CONCLUSIONS: Dehydrobufotenin revealed to be a potential oral drug prototype presenting adequate antimalarial activity and absence of cytotoxicity, therefore should be subjected to further studies.
format Online
Article
Text
id pubmed-7812938
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Centro de Estudos de Venenos e Animais Peçonhentos
record_format MEDLINE/PubMed
spelling pubmed-78129382021-01-29 Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs Banfi, Felipe Finger Krombauer, Gabriela Camila da Fonseca, Amanda Luisa Nunes, Renata Rachide Andrade, Silmara Nunes de Rezende, Millena Alves Chaves, Mariana Helena Monção, Evaldo dos Santos Taranto, Alex Guterres Rodrigues, Domingos de Jesus Vieira, Gerardo Magela de Castro, Whocely Victor Varotti, Fernando de Pilla Sanchez, Bruno Antonio Marinho J Venom Anim Toxins Incl Trop Dis Research BACKGROUND: The resistance against antimalarial drugs represents a global challenge in the fight and control of malaria. The Brazilian biodiversity can be an important tool for research and development of new medicinal products. In this context, toxinology is a multidisciplinary approach on the development of new drugs, including the isolation, purification, and evaluation of the pharmacological activities of natural toxins. The present study aimed to evaluate the cytotoxicity, as well as the antimalarial activity in silico and in vitro of four compounds isolated from Rhinella marina venom as potential oral drug prototypes. METHODS: Four compounds were challenged against 35 target proteins from P. falciparum and screened to evaluate their physicochemical properties using docking assay in Brazilian Malaria Molecular Targets (BraMMT) software and in silico assay in OCTOPUS® software. The in vitro antimalarial activity of the compounds against the 3D7 Plasmodium falciparum clones were assessed using the SYBR Green I based assay (IC(50)). For the cytotoxic tests, the LD(50) was determined in human pulmonary fibroblast cell line using the [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay. RESULTS: All compounds presented a ligand-receptor interaction with ten Plasmodium falciparum-related protein targets, as well as antimalarial activity against chloroquine resistant strain (IC(50) = 3.44 μM to 19.11 μM). Three of them (dehydrobufotenine, marinobufagin, and bufalin) showed adequate conditions for oral drug prototypes, with satisfactory prediction of absorption, permeability, and absence of toxicity. In the cell viability assay, only dehydrobufotenin was selective for the parasite. CONCLUSIONS: Dehydrobufotenin revealed to be a potential oral drug prototype presenting adequate antimalarial activity and absence of cytotoxicity, therefore should be subjected to further studies. Centro de Estudos de Venenos e Animais Peçonhentos 2021-01-08 /pmc/articles/PMC7812938/ /pubmed/33519927 http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0073 Text en This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Banfi, Felipe Finger
Krombauer, Gabriela Camila
da Fonseca, Amanda Luisa
Nunes, Renata Rachide
Andrade, Silmara Nunes
de Rezende, Millena Alves
Chaves, Mariana Helena
Monção, Evaldo dos Santos
Taranto, Alex Guterres
Rodrigues, Domingos de Jesus
Vieira, Gerardo Magela
de Castro, Whocely Victor
Varotti, Fernando de Pilla
Sanchez, Bruno Antonio Marinho
Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs
title Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs
title_full Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs
title_fullStr Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs
title_full_unstemmed Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs
title_short Dehydrobufotenin extracted from the Amazonian toad Rhinella marina (Anura: Bufonidae) as a prototype molecule for the development of antiplasmodial drugs
title_sort dehydrobufotenin extracted from the amazonian toad rhinella marina (anura: bufonidae) as a prototype molecule for the development of antiplasmodial drugs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812938/
https://www.ncbi.nlm.nih.gov/pubmed/33519927
http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0073
work_keys_str_mv AT banfifelipefinger dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT krombauergabrielacamila dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT dafonsecaamandaluisa dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT nunesrenatarachide dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT andradesilmaranunes dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT derezendemillenaalves dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT chavesmarianahelena dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT moncaoevaldodossantos dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT tarantoalexguterres dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT rodriguesdomingosdejesus dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT vieiragerardomagela dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT decastrowhocelyvictor dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT varottifernandodepilla dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs
AT sanchezbrunoantoniomarinho dehydrobufoteninextractedfromtheamazoniantoadrhinellamarinaanurabufonidaeasaprototypemoleculeforthedevelopmentofantiplasmodialdrugs